Recent global market developments have been marked by tariff uncertainties and mixed economic signals, with U.S. stocks experiencing a decline amid trade tensions and cooling job growth, while European markets showed resilience against similar concerns. In this environment, identifying high-growth tech stocks requires a focus on companies that demonstrate strong earnings potential and adaptability to shifting market dynamics.

Click here to see the full list of 1212 stocks from our High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

★★★★☆☆

Pharming Group N.V. is a biopharmaceutical company focused on developing and commercializing protein replacement therapies and precision medicines for rare diseases across the United States, Europe, and internationally, with a market cap of approximately €568.06 million.

Operations: The company generates revenue primarily from its Recombinant Human C1 Esterase Inhibitor business, which reported $285.75 million. Its focus is on developing and commercializing therapies for rare diseases, targeting markets in the United States, Europe, and internationally.

Pharming Group's strategic focus on rare diseases is underscored by its recent advancements in drug development, notably with leniolisib for APDS, a condition first characterized only a decade ago. The company's commitment to innovation is evident from its significant R&D investments, aligning with industry trends towards targeted therapies. Despite current unprofitability and market volatility, Pharming's projected annual earnings growth of 57.21% and revenue growth at 7.9% suggest potential for future profitability, supported by positive Phase III trial outcomes and planned regulatory filings starting in 2025 for pediatric use approvals worldwide. This trajectory is further reinforced by their recent acquisition move to expand their portfolio, indicating an aggressive growth strategy amidst challenging market conditions.